# Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

> **NCT06541405** · EARLY_PHASE1 · RECRUITING · sponsor: **Base Therapeutics (Shanghai) Co., Ltd.** · enrollment: 9 (estimated)

## Conditions studied

- Relapsed/Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** NK520

## Key facts

- **NCT ID:** NCT06541405
- **Lead sponsor:** Base Therapeutics (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2024-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06541405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06541405, "Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06541405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*